

UROLOGIC ONCOLOGY

Seminars and Original Investigations

Table of Contents: Volume 37, Number 5, May 2019

Prostate - Laboratory

- 297.e1** **RPS7 promotes cell migration through targeting epithelial-mesenchymal transition in prostate cancer**
Yingwu Wen, Zesheng An, Baomin Qiao, Changwen Zhang and Zhihong Zhang
- 297.e9** **Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance**
Fang Zhao, Danny Vesprini, Richard S.C. Liu, Ekaterina Olkhov-Mitsel, Laurence H. Klotz, Andrew Loblaw, Stanley K. Liu and Bharati Bapat
- 297.e19** **Programmed death ligand 1 expression in prostate cancer cells is associated with deep changes of the tumor inflammatory infiltrate composition**
Manuel Scimeca, Rita Bonfiglio, Nicoletta Urbano, Chiara Cerroni, Lucia Anemona, Manuela Montanaro, Sara Fazi, Orazio Schillaci, Alessandro Mauriello and Elena Bonanno

Prostate - Clinical

- 298.e1** **The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy**
Christophe K. Mannaerts, Amir Kajtazovic, Olivia A.P. Lodeizen, Maudy Gayet, Marc R.W. Engelbrecht, Gerrit J. Jager, Hessel Wijkstra, Theo M. de Reijke and Harrie P. Beerlage
- 298.e11** **Impact of the estimated blood loss during radical prostatectomy on functional outcomes**
Felix Preisser, Raisa S. Pompe, Georg Salomon, Clemens Rosenbaum, Markus Graefen, Hartwig Huland, Pierre I. Karakiewicz and Derya Tilki
- 298.e19** **Population-based outcomes of men with a single negative prostate biopsy: Importance of continued follow-up among older patients**
Rashid K. Sayyid, Shabbir M.H. Alibhai, Rinku Sutradhar, Maria Eberg, Kinwah Fung, Zachary Klaassen, Hanan Goldberg, Nathan Perlis, Rabii Madi, Martha K. Terris, David R. Urbach and Neil E. Fleshner
- 299.e1** **Difference in MRI-guided biopsy cancer detection rates between individual clinicians**
Niranjan J. Sathianathen, Christopher A. Warlick, Ayman Soubra, Priyamvada Balaji, Gregory J. Metzger, Benjamin Spilseth, Paari Murugan, Maria Ordonez, Christopher J. Weight and Badrinath R. Konety

Bladder - Laboratory

- 299.e7** **High expression of Chitinase 3-like-1 is an unfavorable prognostic factor in urothelial carcinoma of upper urinary tract and urinary bladder**
Ying-En Lee, Ti-Chun Chan, Yu-Feng Tian, Peir-In Liang, Yow-Ling Shiue, Yi-Sheng Chen and Hong-Lin He

Bladder - Clinical

- 299.e19** **Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions**
Earle F. Burgess, Chad Livasy, Aaron Hartman, Myra M. Robinson, James Symanowski, Caroline Naso, Shannon Doherty, Renato Guerrieri, Stephen Riggs, Claud M. Grigg, Peter E. Clark and Derek Raghavan

(contents continued on next page)

Table of Contents (*continued*)

- 300.e1** **Disparities in the diagnostic evaluation of microhematuria and implications for the detection of urologic malignancy**
Richard S. Matulewicz, Alysén L. Demzik, John Oliver DeLancey, Oana Popescu, Danil V Makarov and Joshua J. Meeks
- 300.e9** **Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series**
Maximilian Haider, Christian Ladurner, Roman Mayr, Zafer Tandogdu, Hans-Martin Fritsche, Vincent Fradet, Evi Comploj, Armin Pycha, Francis Lemire, Louis Lacombe, Yves Fradet, Paul Toren and Michele Lodde
- 300.e17** **Prospective implementation of a nonopioid protocol for patients undergoing robot-assisted radical cystectomy with extracorporeal urinary diversion**
François Audenet, Kyrollis Attalla, Morgane Giordano, John Pfail, Marc A. Lubin, Nikhil Waingankar, Daniel Gainsburg, Ketan K. Badani, Alan Sim and John P. Sfakianos

Kidney - Laboratory

- 301.e1** **The *TERT* locus genotypes of rs2736100-CC/CA and rs2736098-AA predict shorter survival in renal cell carcinoma**
Runzhuo Ma, Cheng Liu, Min Lu, Xiaotian Yuan, Guanghui Cheng, Feng Kong, Jian Lu, Klas Strååt, Magnus Björkholm, Lulin Ma and Dawei Xu

Kidney - Clinical

- 301.e11** **The prognostic value of the site of invasion in T3aN0M0 clear cell renal cell carcinoma**
Shengjie Guo, Zefu Liu, Xiangdong Li, Kai Yao, Pei Dong, Dong Chen, Chunxian Liao, Zhaolin Long, Yongqiang Wang, Fangjian Zhou, Xiaobo He and Zhuowei Liu
- 301.e19** **Nephrometry score correlated with tumor proliferative activity in T1 clear cell renal cell carcinoma**
Hiroshi Kikuchi, Takashige Abe, Ryuji Matsumoto, Takahiro Osawa, Satoru Maruyama, Sachiyo Murai and Nobuo Shinohara
- 302.e1** **The prognostic significance of nodal disease burden in patients with lymph node metastases from renal cell carcinoma**
Piotr Zareba and Paul Russo

Seminar Section

- 303** **Clinical Trials in Urology**
Brian F. Chapin
- 305** **An investigator's introduction to statistical considerations in clinical trials**
Kathryn Winter and Stephanie L. Pugh
- 313** **Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research**
Joshua J. Meeks, Amir Goldkorn, Ana M. Aparicio and David J. McConkey
- 318** **Mechanisms and funding opportunities in genitourinary cancer clinical research**
Christopher W. Ryan
- 324** **Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials**
Joseph M. Unger, Riha Vaidya and John L. Gore
- 331** **From the other side: The patient perspective on cancer clinical trials**
Rick Bangs and Tony Crispino
- 336** **Organizing a clinical trial for the new investigator**
Janet Baack Kukreja, Ian M. Thompson Jr and Brian F. Chapin